[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"$fhTkEXtcSedlAZw5fmM1fzbF8JXe_hAkotVpJZ9PoF6o":3},{"sponsor":4,"sponsorVariants":5,"totalTrials":6,"truncated":7,"activeTrials":8,"phase3Count":9,"totalEnrollment":10,"activePrograms":11,"nonDrugCount":12,"topConditions":13,"upcomingReadouts":33,"phaseBuckets":59,"rows":66},"University of Erlangen-Nürnberg Medical School",[4],269,false,45,43,55374,7,196,[14,17,19,21,23,26,29,31],{"name":15,"count":16},"Ulcerative Colitis",10,{"name":18,"count":16},"Hypertension",{"name":20,"count":11},"Cancer",{"name":22,"count":11},"Metabolic Syndrome",{"name":24,"count":25},"Inflammatory Bowel Diseases",6,{"name":27,"count":28},"Crohn's Disease",5,{"name":30,"count":28},"Healthy",{"name":32,"count":28},"Sarcopenia",[34,39,44,49,54],{"nctId":35,"briefTitle":36,"date":37,"intervention":38},"NCT05897047","The smartNTx Trial:Telemedical Management Versus Standard Aftercare in Kidney Transplant Recipients (KTR)","2026-04-30","Additional interventional telemedical management",{"nctId":40,"briefTitle":41,"date":42,"intervention":43},"NCT07352540","Single vs Triple Hyaluronic Acid in Knee Osteoarthritis","2026-08-01","Three intra-articular hyaluronic acid (HA) injections",{"nctId":45,"briefTitle":46,"date":47,"intervention":48},"NCT06560801","Dapagliflozin on Renal Morphology and Renal Perfusion in Patients One Year After Kidney Transplantation","2026-10-31","Dapagliflozin 10mg Tab",{"nctId":50,"briefTitle":51,"date":52,"intervention":53},"NCT03249519","Radiation Therapy or Chemoradiation, Interstitial Brachytherapy in Combination With Hyperthermia in Advanced Cervical Cancer","2094-12-31","Cisplatin",{"nctId":55,"briefTitle":56,"date":57,"intervention":58},"NCT05397262","Organ-preservative Therapy of Bladder Cancer With Radiotherapy or Radiochemotherapy Combined With Hyperthermia","2098-12-31","Chemotherapy 5-Fluorouracil",[60,61,62,63,64,65],"EARLY_PHASE1","PHASE1","PHASE2","PHASE3","PHASE4","NA",[67,92,116,134,156,179,201,219,287,322,348,366,393,411,437,463,481,507,532,550,568,594,619,643,682,711,740,776,815,833,851,869,887,905,923,941,959,977,995,1013,1037,1055,1082,1100,1123,1147,1173,1197,1223,1245,1268,1291,1318,1336,1360,1383,1405,1429,1454,1472,1490,1508,1532,1550,1578,1596,1614,1639,1661,1679,1706,1724,1754,1772,1797,1823,1847,1870,1896,1914,1939,1963,1988,2006,2024,2046,2071,2096,2121,2151,2173,2198,2223,2249,2267,2292,2319,2337,2364,2388,2411,2436,2454,2482,2500],{"intervention":48,"totalTrials":68,"cells":69},1,{"EARLY_PHASE1":70,"PHASE1":73,"PHASE2":75,"PHASE3":77,"PHASE4":79,"NA":90},{"trials":71,"activeCount":72},[],0,{"trials":74,"activeCount":72},[],{"trials":76,"activeCount":72},[],{"trials":78,"activeCount":72},[],{"trials":80,"activeCount":68,"soonestReadout":47},[81],{"nctId":45,"briefTitle":46,"status":82,"phases":83,"primaryCompletion":47,"completion":84,"start":85,"enrollment":86,"conditions":87,"interventions":89},"RECRUITING",[64],"2026-12-31","2023-07-28",48,[88],"Chronic Kidney Diseases",[48],{"trials":91,"activeCount":72},[],{"intervention":43,"totalTrials":68,"cells":93},{"EARLY_PHASE1":94,"PHASE1":96,"PHASE2":98,"PHASE3":100,"PHASE4":112,"NA":114},{"trials":95,"activeCount":72},[],{"trials":97,"activeCount":72},[],{"trials":99,"activeCount":72},[],{"trials":101,"activeCount":68,"soonestReadout":42},[102],{"nctId":40,"briefTitle":41,"status":103,"phases":104,"primaryCompletion":42,"completion":105,"start":106,"enrollment":107,"conditions":108,"interventions":110},"ACTIVE_NOT_RECRUITING",[62,63],"2026-09-01","2026-01-15",46,[109],"Osteoarthritis, Knee",[43,111],"One intra-articular hyaluronic acid (HA)",{"trials":113,"activeCount":72},[],{"trials":115,"activeCount":72},[],{"intervention":111,"totalTrials":68,"cells":117},{"EARLY_PHASE1":118,"PHASE1":120,"PHASE2":122,"PHASE3":124,"PHASE4":130,"NA":132},{"trials":119,"activeCount":72},[],{"trials":121,"activeCount":72},[],{"trials":123,"activeCount":72},[],{"trials":125,"activeCount":68,"soonestReadout":42},[126],{"nctId":40,"briefTitle":41,"status":103,"phases":127,"primaryCompletion":42,"completion":105,"start":106,"enrollment":107,"conditions":128,"interventions":129},[62,63],[109],[43,111],{"trials":131,"activeCount":72},[],{"trials":133,"activeCount":72},[],{"intervention":53,"totalTrials":68,"cells":135},{"EARLY_PHASE1":136,"PHASE1":138,"PHASE2":140,"PHASE3":142,"PHASE4":144,"NA":146},{"trials":137,"activeCount":72},[],{"trials":139,"activeCount":72},[],{"trials":141,"activeCount":72},[],{"trials":143,"activeCount":72},[],{"trials":145,"activeCount":72},[],{"trials":147,"activeCount":68,"soonestReadout":52},[148],{"nctId":50,"briefTitle":51,"status":82,"phases":149,"primaryCompletion":52,"completion":150,"start":151,"enrollment":152,"conditions":153,"interventions":155},[65],"2099-12-31","2017-08-01",999,[154],"Cervical Cancer",[53],{"intervention":38,"totalTrials":68,"cells":157},{"EARLY_PHASE1":158,"PHASE1":160,"PHASE2":162,"PHASE3":164,"PHASE4":166,"NA":168},{"trials":159,"activeCount":72},[],{"trials":161,"activeCount":72},[],{"trials":163,"activeCount":72},[],{"trials":165,"activeCount":72},[],{"trials":167,"activeCount":72},[],{"trials":169,"activeCount":68,"soonestReadout":37},[170],{"nctId":35,"briefTitle":36,"status":103,"phases":171,"primaryCompletion":37,"completion":172,"start":173,"enrollment":174,"conditions":175,"interventions":178},[65],"2026-08-30","2023-05-15",384,[176,177],"Kidney Transplant Rejection","Kidney Transplant Failure",[38],{"intervention":58,"totalTrials":68,"cells":180},{"EARLY_PHASE1":181,"PHASE1":183,"PHASE2":185,"PHASE3":187,"PHASE4":189,"NA":191},{"trials":182,"activeCount":72},[],{"trials":184,"activeCount":72},[],{"trials":186,"activeCount":72},[],{"trials":188,"activeCount":72},[],{"trials":190,"activeCount":72},[],{"trials":192,"activeCount":68,"soonestReadout":57},[193],{"nctId":55,"briefTitle":56,"status":82,"phases":194,"primaryCompletion":57,"completion":150,"start":195,"enrollment":196,"conditions":197,"interventions":199},[65],"2017-03-29",1000,[198],"Bladder Cancer",[58,200],"Chemotherapy Cisplatin",{"intervention":200,"totalTrials":68,"cells":202},{"EARLY_PHASE1":203,"PHASE1":205,"PHASE2":207,"PHASE3":209,"PHASE4":211,"NA":213},{"trials":204,"activeCount":72},[],{"trials":206,"activeCount":72},[],{"trials":208,"activeCount":72},[],{"trials":210,"activeCount":72},[],{"trials":212,"activeCount":72},[],{"trials":214,"activeCount":68,"soonestReadout":57},[215],{"nctId":55,"briefTitle":56,"status":82,"phases":216,"primaryCompletion":57,"completion":150,"start":195,"enrollment":196,"conditions":217,"interventions":218},[65],[198],[58,200],{"intervention":220,"totalTrials":221,"cells":222},"Secukinumab",3,{"EARLY_PHASE1":223,"PHASE1":225,"PHASE2":227,"PHASE3":243,"PHASE4":272,"NA":285},{"trials":224,"activeCount":72},[],{"trials":226,"activeCount":72},[],{"trials":228,"activeCount":72},[229],{"nctId":230,"briefTitle":231,"status":232,"phases":233,"primaryCompletion":234,"completion":235,"start":236,"enrollment":237,"conditions":238,"interventions":241},"NCT02483234","Psoriasis-Arthritis & Bone Program","COMPLETED",[62],"2018-06-30","2018-09-30","2015-05-31",40,[239,240],"Psoriasis","Psoriatic Arthritis",[242],"secukinumab",{"trials":244,"activeCount":72},[245],{"nctId":246,"briefTitle":247,"status":248,"phases":249,"primaryCompletion":250,"completion":251,"start":252,"enrollment":253,"conditions":254,"interventions":257},"NCT04610476","Impact of Tapering Immunosuppressants on Maintaining Minimal Disease Activity in Adult Subjects With Psoriatic Arthritis","UNKNOWN",[63],"2024-10-19","2025-10-19","2020-10-19",270,[240,255,256],"Withdrawal","Reduction",[258,259,260,261,262,263,264,265,266,267,268,269,220,270,271],"Prednisolone","Sulfasalazine","Leflunomide","Methotrexate","Tofacitinib","Apremilast","Etanercept","Adalimumab","Infliximab","Certolizumab pegol","Golimumab","Abatacept","Ixekizumab","Ustekinumab",{"trials":273,"activeCount":72},[274],{"nctId":275,"briefTitle":276,"status":248,"phases":277,"primaryCompletion":278,"completion":279,"start":280,"enrollment":16,"conditions":281,"interventions":284},"NCT04887597","EBIO - Enthesitis Biopsy Study",[64],"2022-03","2022-09","2019-03-18",[240,282,283],"Enthesitis","Biopsy",[220],{"trials":286,"activeCount":72},[],{"intervention":288,"totalTrials":289,"cells":290},"Hydromorphone",2,{"EARLY_PHASE1":291,"PHASE1":293,"PHASE2":295,"PHASE3":297,"PHASE4":299,"NA":320},{"trials":292,"activeCount":72},[],{"trials":294,"activeCount":72},[],{"trials":296,"activeCount":72},[],{"trials":298,"activeCount":72},[],{"trials":300,"activeCount":72},[301,311],{"nctId":302,"briefTitle":303,"status":232,"phases":304,"primaryCompletion":305,"completion":305,"start":306,"enrollment":307,"conditions":308,"interventions":310},"NCT02035709","Postoperative Pain Therapy With Hydromorphone Using TCI-PCA",[64],"2015-04","2013-12",50,[309],"Postoperative Pain",[288],{"nctId":312,"briefTitle":313,"status":232,"phases":314,"primaryCompletion":315,"completion":315,"start":305,"enrollment":307,"conditions":316,"interventions":318},"NCT02483221","Postoperative Pain Therapy With Hydromorphone TCI-PCA vs. Morphine PCA",[64],"2016-12-01",[317],"Acute Postoperative Pain",[288,319],"Morphine",{"trials":321,"activeCount":72},[],{"intervention":323,"totalTrials":68,"cells":324},"Mirtazapine",{"EARLY_PHASE1":325,"PHASE1":327,"PHASE2":329,"PHASE3":331,"PHASE4":333,"NA":346},{"trials":326,"activeCount":72},[],{"trials":328,"activeCount":72},[],{"trials":330,"activeCount":72},[],{"trials":332,"activeCount":72},[],{"trials":334,"activeCount":72},[335],{"nctId":336,"briefTitle":337,"status":232,"phases":338,"primaryCompletion":339,"completion":339,"start":340,"enrollment":341,"conditions":342,"interventions":344},"NCT00150839","Hippocampal Volume in Young Patients With Major Depression Before and After Combined Antidepressive Therapy",[64],"2009-12","2006-03",80,[343],"Depressive Disorder, Major",[323,345],"Venlafaxine",{"trials":347,"activeCount":72},[],{"intervention":345,"totalTrials":68,"cells":349},{"EARLY_PHASE1":350,"PHASE1":352,"PHASE2":354,"PHASE3":356,"PHASE4":358,"NA":364},{"trials":351,"activeCount":72},[],{"trials":353,"activeCount":72},[],{"trials":355,"activeCount":72},[],{"trials":357,"activeCount":72},[],{"trials":359,"activeCount":72},[360],{"nctId":336,"briefTitle":337,"status":232,"phases":361,"primaryCompletion":339,"completion":339,"start":340,"enrollment":341,"conditions":362,"interventions":363},[64],[343],[323,345],{"trials":365,"activeCount":72},[],{"intervention":367,"totalTrials":68,"cells":368},"Evolocumab Prefilled Syringe",{"EARLY_PHASE1":369,"PHASE1":371,"PHASE2":373,"PHASE3":375,"PHASE4":377,"NA":391},{"trials":370,"activeCount":72},[],{"trials":372,"activeCount":72},[],{"trials":374,"activeCount":72},[],{"trials":376,"activeCount":72},[],{"trials":378,"activeCount":72},[379],{"nctId":380,"briefTitle":381,"status":232,"phases":382,"primaryCompletion":383,"completion":384,"start":385,"enrollment":386,"conditions":387,"interventions":389},"NCT03626831","Effect of Evolocumab on Vascular Function",[64],"2021-04-15","2021-07-12","2019-04-04",105,[388],"Atherosclerotic Cardiovascular Disease",[367,390],"Placebos",{"trials":392,"activeCount":72},[],{"intervention":390,"totalTrials":68,"cells":394},{"EARLY_PHASE1":395,"PHASE1":397,"PHASE2":399,"PHASE3":401,"PHASE4":403,"NA":409},{"trials":396,"activeCount":72},[],{"trials":398,"activeCount":72},[],{"trials":400,"activeCount":72},[],{"trials":402,"activeCount":72},[],{"trials":404,"activeCount":72},[405],{"nctId":380,"briefTitle":381,"status":232,"phases":406,"primaryCompletion":383,"completion":384,"start":385,"enrollment":386,"conditions":407,"interventions":408},[64],[388],[367,390],{"trials":410,"activeCount":72},[],{"intervention":412,"totalTrials":68,"cells":413},"Abatacept 125 MG\u002FML",{"EARLY_PHASE1":414,"PHASE1":416,"PHASE2":418,"PHASE3":420,"PHASE4":422,"NA":435},{"trials":415,"activeCount":72},[],{"trials":417,"activeCount":72},[],{"trials":419,"activeCount":72},[],{"trials":421,"activeCount":72},[],{"trials":423,"activeCount":72},[424],{"nctId":425,"briefTitle":426,"status":248,"phases":427,"primaryCompletion":428,"completion":429,"start":430,"enrollment":431,"conditions":432,"interventions":434},"NCT04106804","Abatacept Bone Effects in Psoriatic Arthritis With Bone Biomarker",[64],"2021-08","2022-08","2018-06-06",20,[433],"Evaluate Bone Changes in Patients With PsA",[412],{"trials":436,"activeCount":72},[],{"intervention":438,"totalTrials":68,"cells":439},"Rilmenidine",{"EARLY_PHASE1":440,"PHASE1":442,"PHASE2":444,"PHASE3":446,"PHASE4":448,"NA":461},{"trials":441,"activeCount":72},[],{"trials":443,"activeCount":72},[],{"trials":445,"activeCount":72},[],{"trials":447,"activeCount":72},[],{"trials":449,"activeCount":72},[450],{"nctId":451,"briefTitle":452,"status":453,"phases":454,"primaryCompletion":455,"completion":455,"start":456,"enrollment":72,"conditions":457,"interventions":459},"NCT00892892","Sympathetic Nerve Activity in Renal Failure","WITHDRAWN",[64],"2011-06","2009-11",[458,18],"Chronic Kidney Disease",[438,460],"Nitrendipine",{"trials":462,"activeCount":72},[],{"intervention":460,"totalTrials":68,"cells":464},{"EARLY_PHASE1":465,"PHASE1":467,"PHASE2":469,"PHASE3":471,"PHASE4":473,"NA":479},{"trials":466,"activeCount":72},[],{"trials":468,"activeCount":72},[],{"trials":470,"activeCount":72},[],{"trials":472,"activeCount":72},[],{"trials":474,"activeCount":72},[475],{"nctId":451,"briefTitle":452,"status":453,"phases":476,"primaryCompletion":455,"completion":455,"start":456,"enrollment":72,"conditions":477,"interventions":478},[64],[458,18],[438,460],{"trials":480,"activeCount":72},[],{"intervention":482,"totalTrials":68,"cells":483},"Reduction of cyclosporine A (CSA)-dosing",{"EARLY_PHASE1":484,"PHASE1":486,"PHASE2":488,"PHASE3":490,"PHASE4":492,"NA":505},{"trials":485,"activeCount":72},[],{"trials":487,"activeCount":72},[],{"trials":489,"activeCount":72},[],{"trials":491,"activeCount":72},[],{"trials":493,"activeCount":72},[494],{"nctId":495,"briefTitle":496,"status":497,"phases":498,"primaryCompletion":499,"completion":500,"start":501,"enrollment":307,"conditions":502,"interventions":504},"NCT00663455","Randomized Study to Reduce Calcineurininhibitor Toxicity in Pediatric and Adolescent Kidney Transplant Recipients","TERMINATED",[64],"2012-12","2013-06","2008-12",[503],"Kidney Transplant",[482],{"trials":506,"activeCount":72},[],{"intervention":508,"totalTrials":68,"cells":509},"Physioneal 35",{"EARLY_PHASE1":510,"PHASE1":512,"PHASE2":514,"PHASE3":516,"PHASE4":518,"NA":530},{"trials":511,"activeCount":72},[],{"trials":513,"activeCount":72},[],{"trials":515,"activeCount":72},[],{"trials":517,"activeCount":72},[],{"trials":519,"activeCount":72},[520],{"nctId":521,"briefTitle":522,"status":497,"phases":523,"primaryCompletion":524,"completion":524,"start":525,"enrollment":28,"conditions":526,"interventions":528},"NCT00776191","Randomized Multicenter Cross-over Study to Compare the Effect of Physioneal 35 to 40 on the Protein Metabolism",[64],"2012-05","2008-09",[527],"Endstage Renal Disease",[508,529],"Physioneal 40",{"trials":531,"activeCount":72},[],{"intervention":529,"totalTrials":68,"cells":533},{"EARLY_PHASE1":534,"PHASE1":536,"PHASE2":538,"PHASE3":540,"PHASE4":542,"NA":548},{"trials":535,"activeCount":72},[],{"trials":537,"activeCount":72},[],{"trials":539,"activeCount":72},[],{"trials":541,"activeCount":72},[],{"trials":543,"activeCount":72},[544],{"nctId":521,"briefTitle":522,"status":497,"phases":545,"primaryCompletion":524,"completion":524,"start":525,"enrollment":28,"conditions":546,"interventions":547},[64],[527],[508,529],{"trials":549,"activeCount":72},[],{"intervention":319,"totalTrials":68,"cells":551},{"EARLY_PHASE1":552,"PHASE1":554,"PHASE2":556,"PHASE3":558,"PHASE4":560,"NA":566},{"trials":553,"activeCount":72},[],{"trials":555,"activeCount":72},[],{"trials":557,"activeCount":72},[],{"trials":559,"activeCount":72},[],{"trials":561,"activeCount":72},[562],{"nctId":312,"briefTitle":313,"status":232,"phases":563,"primaryCompletion":315,"completion":315,"start":305,"enrollment":307,"conditions":564,"interventions":565},[64],[317],[288,319],{"trials":567,"activeCount":72},[],{"intervention":569,"totalTrials":68,"cells":570},"Semaglutide Pen Injector",{"EARLY_PHASE1":571,"PHASE1":573,"PHASE2":575,"PHASE3":577,"PHASE4":579,"NA":592},{"trials":572,"activeCount":72},[],{"trials":574,"activeCount":72},[],{"trials":576,"activeCount":72},[],{"trials":578,"activeCount":72},[],{"trials":580,"activeCount":72},[581],{"nctId":582,"briefTitle":583,"status":232,"phases":584,"primaryCompletion":585,"completion":586,"start":587,"enrollment":588,"conditions":589,"interventions":591},"NCT05303857","Analyse the Effect of Semaglutide on Vascular Structure and Function in Patients With Early Type 2 Diabetes",[64],"2023-12-15","2025-04-17","2022-03-03",107,[590],"Diabetes Mellitus, Type 2",[569],{"trials":593,"activeCount":72},[],{"intervention":595,"totalTrials":68,"cells":596},"Quetiapine fumarate",{"EARLY_PHASE1":597,"PHASE1":599,"PHASE2":601,"PHASE3":603,"PHASE4":605,"NA":617},{"trials":598,"activeCount":72},[],{"trials":600,"activeCount":72},[],{"trials":602,"activeCount":72},[],{"trials":604,"activeCount":72},[],{"trials":606,"activeCount":72},[607],{"nctId":608,"briefTitle":609,"status":232,"phases":610,"primaryCompletion":611,"completion":611,"start":612,"enrollment":613,"conditions":614,"interventions":616},"NCT00370500","Quetiapine and the Dopaminergic Epigenetic Control",[64],"2008-07","2007-04",100,[615],"Schizophrenia",[595],{"trials":618,"activeCount":72},[],{"intervention":620,"totalTrials":68,"cells":621},"Sufentanil, Hydromorphone",{"EARLY_PHASE1":622,"PHASE1":624,"PHASE2":626,"PHASE3":628,"PHASE4":630,"NA":641},{"trials":623,"activeCount":72},[],{"trials":625,"activeCount":72},[],{"trials":627,"activeCount":72},[],{"trials":629,"activeCount":72},[],{"trials":631,"activeCount":72},[632],{"nctId":633,"briefTitle":634,"status":232,"phases":635,"primaryCompletion":636,"completion":636,"start":637,"enrollment":307,"conditions":638,"interventions":640},"NCT01490268","Pain Therapy After Elective Cardiac Surgery",[64],"2012-09","2011-11",[639],"Pain",[620,620],{"trials":642,"activeCount":72},[],{"intervention":269,"totalTrials":221,"cells":644},{"EARLY_PHASE1":645,"PHASE1":647,"PHASE2":649,"PHASE3":661,"PHASE4":678,"NA":680},{"trials":646,"activeCount":72},[],{"trials":648,"activeCount":72},[],{"trials":650,"activeCount":72},[651],{"nctId":652,"briefTitle":653,"status":248,"phases":654,"primaryCompletion":655,"completion":656,"start":657,"enrollment":431,"conditions":658,"interventions":660},"NCT04120831","TOLERA: Tolerance Enhancement in RA",[62],"2020-09-01","2022-12-01","2019-10-07",[659],"Rheumatoid Arthritis",[269],{"trials":662,"activeCount":72},[663,667],{"nctId":246,"briefTitle":247,"status":248,"phases":664,"primaryCompletion":250,"completion":251,"start":252,"enrollment":253,"conditions":665,"interventions":666},[63],[240,255,256],[258,259,260,261,262,263,264,265,266,267,268,269,220,270,271],{"nctId":668,"briefTitle":669,"status":232,"phases":670,"primaryCompletion":671,"completion":671,"start":672,"enrollment":673,"conditions":674,"interventions":677},"NCT02778906","Abatacept Reversing Subclinical Inflammation as Measured by MRI in ACPA Positive Arthralgia",[63],"2019-12","2014-11",98,[675,676],"Arthralgia","Arthritis",[269],{"trials":679,"activeCount":72},[],{"trials":681,"activeCount":72},[],{"intervention":263,"totalTrials":289,"cells":683},{"EARLY_PHASE1":684,"PHASE1":686,"PHASE2":688,"PHASE3":701,"PHASE4":707,"NA":709},{"trials":685,"activeCount":72},[],{"trials":687,"activeCount":72},[],{"trials":689,"activeCount":72},[690],{"nctId":691,"briefTitle":692,"status":232,"phases":693,"primaryCompletion":694,"completion":695,"start":696,"enrollment":697,"conditions":698,"interventions":700},"NCT01200472","Efficacy Study of Apremilast (CC-10004) in Subjects With Erosive Hand Osteoarthritis",[62],"2013-08","2013-10","2010-08",30,[699],"Erosive Osteoarthritis of the Hand",[263],{"trials":702,"activeCount":72},[703],{"nctId":246,"briefTitle":247,"status":248,"phases":704,"primaryCompletion":250,"completion":251,"start":252,"enrollment":253,"conditions":705,"interventions":706},[63],[240,255,256],[258,259,260,261,262,263,264,265,266,267,268,269,220,270,271],{"trials":708,"activeCount":72},[],{"trials":710,"activeCount":72},[],{"intervention":267,"totalTrials":289,"cells":712},{"EARLY_PHASE1":713,"PHASE1":715,"PHASE2":717,"PHASE3":719,"PHASE4":736,"NA":738},{"trials":714,"activeCount":72},[],{"trials":716,"activeCount":72},[],{"trials":718,"activeCount":72},[],{"trials":720,"activeCount":72},[721,725],{"nctId":246,"briefTitle":247,"status":248,"phases":722,"primaryCompletion":250,"completion":251,"start":252,"enrollment":253,"conditions":723,"interventions":724},[63],[240,255,256],[258,259,260,261,262,263,264,265,266,267,268,269,220,270,271],{"nctId":726,"briefTitle":727,"status":232,"phases":728,"primaryCompletion":729,"completion":730,"start":731,"enrollment":732,"conditions":733,"interventions":734},"NCT01864265","Prediction of Response to Certolizumab Pegol Treatment by Functional MRI of the Brain",[63],"2019-06-30","2020-01-10","2013-07",156,[659],[735],"Certolizumab Pegol",{"trials":737,"activeCount":72},[],{"trials":739,"activeCount":72},[],{"intervention":741,"totalTrials":289,"cells":742},"eplerenone",{"EARLY_PHASE1":743,"PHASE1":745,"PHASE2":747,"PHASE3":749,"PHASE4":772,"NA":774},{"trials":744,"activeCount":72},[],{"trials":746,"activeCount":72},[],{"trials":748,"activeCount":72},[],{"trials":750,"activeCount":72},[751,761],{"nctId":752,"briefTitle":753,"status":232,"phases":754,"primaryCompletion":755,"completion":611,"start":756,"enrollment":757,"conditions":758,"interventions":760},"NCT00138944","Effectiveness of Eplerenone to Improve Target Organ Damage in Patients With Resistant Arterial Hypertension",[63],"2008-05","2007-01",85,[759],"Essential Hypertension",[741],{"nctId":762,"briefTitle":763,"status":232,"phases":764,"primaryCompletion":499,"completion":765,"start":766,"enrollment":767,"conditions":768,"interventions":770},"NCT01319344","Effect of Eplerenone on Endothelial Function in Metabolic Syndrome",[63],"2013-04","2010-09",42,[22,769],"Endothelial Dysfunction",[771],"Eplerenone",{"trials":773,"activeCount":72},[],{"trials":775,"activeCount":72},[],{"intervention":777,"totalTrials":289,"cells":778},"5-Fluorouracil",{"EARLY_PHASE1":779,"PHASE1":781,"PHASE2":783,"PHASE3":797,"PHASE4":811,"NA":813},{"trials":780,"activeCount":72},[],{"trials":782,"activeCount":72},[],{"trials":784,"activeCount":72},[785],{"nctId":786,"briefTitle":787,"status":248,"phases":788,"primaryCompletion":789,"completion":790,"start":636,"enrollment":791,"conditions":792,"interventions":794},"NCT01716949","Neoadjuvant Chemoradiation With 5-FU(or Capecitabine) and Oxaliplatin Combined With Hyperthermia in Rectal Cancer",[61,62],"2022-06","2023-06",59,[793],"Rectal Cancer",[777,795,796],"Capecitabine","Oxaliplatin",{"trials":798,"activeCount":72},[799],{"nctId":800,"briefTitle":801,"status":248,"phases":802,"primaryCompletion":803,"completion":804,"start":805,"enrollment":806,"conditions":807,"interventions":809},"NCT02369939","Effects of Deep Regional Hyperthermia in Patients With Anal Carcinoma Treated by Standard Radiochemotherapy",[63],"2017-12","2021-04","2014-12",118,[808],"Anal Carcinoma",[810,777],"Mitomycin C",{"trials":812,"activeCount":72},[],{"trials":814,"activeCount":72},[],{"intervention":258,"totalTrials":68,"cells":816},{"EARLY_PHASE1":817,"PHASE1":819,"PHASE2":821,"PHASE3":823,"PHASE4":829,"NA":831},{"trials":818,"activeCount":72},[],{"trials":820,"activeCount":72},[],{"trials":822,"activeCount":72},[],{"trials":824,"activeCount":72},[825],{"nctId":246,"briefTitle":247,"status":248,"phases":826,"primaryCompletion":250,"completion":251,"start":252,"enrollment":253,"conditions":827,"interventions":828},[63],[240,255,256],[258,259,260,261,262,263,264,265,266,267,268,269,220,270,271],{"trials":830,"activeCount":72},[],{"trials":832,"activeCount":72},[],{"intervention":259,"totalTrials":68,"cells":834},{"EARLY_PHASE1":835,"PHASE1":837,"PHASE2":839,"PHASE3":841,"PHASE4":847,"NA":849},{"trials":836,"activeCount":72},[],{"trials":838,"activeCount":72},[],{"trials":840,"activeCount":72},[],{"trials":842,"activeCount":72},[843],{"nctId":246,"briefTitle":247,"status":248,"phases":844,"primaryCompletion":250,"completion":251,"start":252,"enrollment":253,"conditions":845,"interventions":846},[63],[240,255,256],[258,259,260,261,262,263,264,265,266,267,268,269,220,270,271],{"trials":848,"activeCount":72},[],{"trials":850,"activeCount":72},[],{"intervention":260,"totalTrials":68,"cells":852},{"EARLY_PHASE1":853,"PHASE1":855,"PHASE2":857,"PHASE3":859,"PHASE4":865,"NA":867},{"trials":854,"activeCount":72},[],{"trials":856,"activeCount":72},[],{"trials":858,"activeCount":72},[],{"trials":860,"activeCount":72},[861],{"nctId":246,"briefTitle":247,"status":248,"phases":862,"primaryCompletion":250,"completion":251,"start":252,"enrollment":253,"conditions":863,"interventions":864},[63],[240,255,256],[258,259,260,261,262,263,264,265,266,267,268,269,220,270,271],{"trials":866,"activeCount":72},[],{"trials":868,"activeCount":72},[],{"intervention":261,"totalTrials":68,"cells":870},{"EARLY_PHASE1":871,"PHASE1":873,"PHASE2":875,"PHASE3":877,"PHASE4":883,"NA":885},{"trials":872,"activeCount":72},[],{"trials":874,"activeCount":72},[],{"trials":876,"activeCount":72},[],{"trials":878,"activeCount":72},[879],{"nctId":246,"briefTitle":247,"status":248,"phases":880,"primaryCompletion":250,"completion":251,"start":252,"enrollment":253,"conditions":881,"interventions":882},[63],[240,255,256],[258,259,260,261,262,263,264,265,266,267,268,269,220,270,271],{"trials":884,"activeCount":72},[],{"trials":886,"activeCount":72},[],{"intervention":262,"totalTrials":68,"cells":888},{"EARLY_PHASE1":889,"PHASE1":891,"PHASE2":893,"PHASE3":895,"PHASE4":901,"NA":903},{"trials":890,"activeCount":72},[],{"trials":892,"activeCount":72},[],{"trials":894,"activeCount":72},[],{"trials":896,"activeCount":72},[897],{"nctId":246,"briefTitle":247,"status":248,"phases":898,"primaryCompletion":250,"completion":251,"start":252,"enrollment":253,"conditions":899,"interventions":900},[63],[240,255,256],[258,259,260,261,262,263,264,265,266,267,268,269,220,270,271],{"trials":902,"activeCount":72},[],{"trials":904,"activeCount":72},[],{"intervention":264,"totalTrials":68,"cells":906},{"EARLY_PHASE1":907,"PHASE1":909,"PHASE2":911,"PHASE3":913,"PHASE4":919,"NA":921},{"trials":908,"activeCount":72},[],{"trials":910,"activeCount":72},[],{"trials":912,"activeCount":72},[],{"trials":914,"activeCount":72},[915],{"nctId":246,"briefTitle":247,"status":248,"phases":916,"primaryCompletion":250,"completion":251,"start":252,"enrollment":253,"conditions":917,"interventions":918},[63],[240,255,256],[258,259,260,261,262,263,264,265,266,267,268,269,220,270,271],{"trials":920,"activeCount":72},[],{"trials":922,"activeCount":72},[],{"intervention":265,"totalTrials":68,"cells":924},{"EARLY_PHASE1":925,"PHASE1":927,"PHASE2":929,"PHASE3":931,"PHASE4":937,"NA":939},{"trials":926,"activeCount":72},[],{"trials":928,"activeCount":72},[],{"trials":930,"activeCount":72},[],{"trials":932,"activeCount":72},[933],{"nctId":246,"briefTitle":247,"status":248,"phases":934,"primaryCompletion":250,"completion":251,"start":252,"enrollment":253,"conditions":935,"interventions":936},[63],[240,255,256],[258,259,260,261,262,263,264,265,266,267,268,269,220,270,271],{"trials":938,"activeCount":72},[],{"trials":940,"activeCount":72},[],{"intervention":266,"totalTrials":68,"cells":942},{"EARLY_PHASE1":943,"PHASE1":945,"PHASE2":947,"PHASE3":949,"PHASE4":955,"NA":957},{"trials":944,"activeCount":72},[],{"trials":946,"activeCount":72},[],{"trials":948,"activeCount":72},[],{"trials":950,"activeCount":72},[951],{"nctId":246,"briefTitle":247,"status":248,"phases":952,"primaryCompletion":250,"completion":251,"start":252,"enrollment":253,"conditions":953,"interventions":954},[63],[240,255,256],[258,259,260,261,262,263,264,265,266,267,268,269,220,270,271],{"trials":956,"activeCount":72},[],{"trials":958,"activeCount":72},[],{"intervention":268,"totalTrials":68,"cells":960},{"EARLY_PHASE1":961,"PHASE1":963,"PHASE2":965,"PHASE3":967,"PHASE4":973,"NA":975},{"trials":962,"activeCount":72},[],{"trials":964,"activeCount":72},[],{"trials":966,"activeCount":72},[],{"trials":968,"activeCount":72},[969],{"nctId":246,"briefTitle":247,"status":248,"phases":970,"primaryCompletion":250,"completion":251,"start":252,"enrollment":253,"conditions":971,"interventions":972},[63],[240,255,256],[258,259,260,261,262,263,264,265,266,267,268,269,220,270,271],{"trials":974,"activeCount":72},[],{"trials":976,"activeCount":72},[],{"intervention":270,"totalTrials":68,"cells":978},{"EARLY_PHASE1":979,"PHASE1":981,"PHASE2":983,"PHASE3":985,"PHASE4":991,"NA":993},{"trials":980,"activeCount":72},[],{"trials":982,"activeCount":72},[],{"trials":984,"activeCount":72},[],{"trials":986,"activeCount":72},[987],{"nctId":246,"briefTitle":247,"status":248,"phases":988,"primaryCompletion":250,"completion":251,"start":252,"enrollment":253,"conditions":989,"interventions":990},[63],[240,255,256],[258,259,260,261,262,263,264,265,266,267,268,269,220,270,271],{"trials":992,"activeCount":72},[],{"trials":994,"activeCount":72},[],{"intervention":271,"totalTrials":68,"cells":996},{"EARLY_PHASE1":997,"PHASE1":999,"PHASE2":1001,"PHASE3":1003,"PHASE4":1009,"NA":1011},{"trials":998,"activeCount":72},[],{"trials":1000,"activeCount":72},[],{"trials":1002,"activeCount":72},[],{"trials":1004,"activeCount":72},[1005],{"nctId":246,"briefTitle":247,"status":248,"phases":1006,"primaryCompletion":250,"completion":251,"start":252,"enrollment":253,"conditions":1007,"interventions":1008},[63],[240,255,256],[258,259,260,261,262,263,264,265,266,267,268,269,220,270,271],{"trials":1010,"activeCount":72},[],{"trials":1012,"activeCount":72},[],{"intervention":1014,"totalTrials":68,"cells":1015},"Buspirone",{"EARLY_PHASE1":1016,"PHASE1":1018,"PHASE2":1020,"PHASE3":1022,"PHASE4":1033,"NA":1035},{"trials":1017,"activeCount":72},[],{"trials":1019,"activeCount":72},[],{"trials":1021,"activeCount":72},[],{"trials":1023,"activeCount":72},[1024],{"nctId":1025,"briefTitle":1026,"status":497,"phases":1027,"primaryCompletion":1028,"completion":1028,"start":731,"enrollment":673,"conditions":1029,"interventions":1031},"NCT01833312","Cooling Plus Best Medical Treatment Versus Best Medical Treatment Alone for Acute Ischaemic Stroke",[63],"2018-07-31",[1030],"Acute Ischemic Stroke",[1014,1032],"Pethidine",{"trials":1034,"activeCount":72},[],{"trials":1036,"activeCount":72},[],{"intervention":1032,"totalTrials":68,"cells":1038},{"EARLY_PHASE1":1039,"PHASE1":1041,"PHASE2":1043,"PHASE3":1045,"PHASE4":1051,"NA":1053},{"trials":1040,"activeCount":72},[],{"trials":1042,"activeCount":72},[],{"trials":1044,"activeCount":72},[],{"trials":1046,"activeCount":72},[1047],{"nctId":1025,"briefTitle":1026,"status":497,"phases":1048,"primaryCompletion":1028,"completion":1028,"start":731,"enrollment":673,"conditions":1049,"interventions":1050},[63],[1030],[1014,1032],{"trials":1052,"activeCount":72},[],{"trials":1054,"activeCount":72},[],{"intervention":1056,"totalTrials":68,"cells":1057},"5-FU and oxaliplatin",{"EARLY_PHASE1":1058,"PHASE1":1060,"PHASE2":1062,"PHASE3":1064,"PHASE4":1078,"NA":1080},{"trials":1059,"activeCount":72},[],{"trials":1061,"activeCount":72},[],{"trials":1063,"activeCount":72},[],{"trials":1065,"activeCount":72},[1066],{"nctId":1067,"briefTitle":1068,"status":232,"phases":1069,"primaryCompletion":1070,"completion":1071,"start":1072,"enrollment":1073,"conditions":1074,"interventions":1076},"NCT00349076","Neoadjuvant Chemoradiotherapy and Adjuvant Chemotherapy With 5-Fluorouracil and Oxaliplatin Versus 5-Fluorouracil Alone in Rectal Cancer",[63],"2015-12","2016-06","2006-07",1256,[1075],"Rectal Neoplasms",[1056,1077],"5-FU",{"trials":1079,"activeCount":72},[],{"trials":1081,"activeCount":72},[],{"intervention":1077,"totalTrials":68,"cells":1083},{"EARLY_PHASE1":1084,"PHASE1":1086,"PHASE2":1088,"PHASE3":1090,"PHASE4":1096,"NA":1098},{"trials":1085,"activeCount":72},[],{"trials":1087,"activeCount":72},[],{"trials":1089,"activeCount":72},[],{"trials":1091,"activeCount":72},[1092],{"nctId":1067,"briefTitle":1068,"status":232,"phases":1093,"primaryCompletion":1070,"completion":1071,"start":1072,"enrollment":1073,"conditions":1094,"interventions":1095},[63],[1075],[1056,1077],{"trials":1097,"activeCount":72},[],{"trials":1099,"activeCount":72},[],{"intervention":1101,"totalTrials":68,"cells":1102},"L-Arginine",{"EARLY_PHASE1":1103,"PHASE1":1105,"PHASE2":1107,"PHASE3":1109,"PHASE4":1119,"NA":1121},{"trials":1104,"activeCount":72},[],{"trials":1106,"activeCount":72},[],{"trials":1108,"activeCount":72},[],{"trials":1110,"activeCount":72},[1111],{"nctId":1112,"briefTitle":1113,"status":232,"phases":1114,"primaryCompletion":339,"completion":339,"start":1115,"enrollment":1116,"conditions":1117,"interventions":1118},"NCT00137124","L-Arginine Metabolism in Essential Hypertension",[62,63],"2006-05",120,[759],[1101],{"trials":1120,"activeCount":72},[],{"trials":1122,"activeCount":72},[],{"intervention":1124,"totalTrials":68,"cells":1125},"Saxagliptin",{"EARLY_PHASE1":1126,"PHASE1":1128,"PHASE2":1130,"PHASE3":1132,"PHASE4":1143,"NA":1145},{"trials":1127,"activeCount":72},[],{"trials":1129,"activeCount":72},[],{"trials":1131,"activeCount":72},[],{"trials":1133,"activeCount":72},[1134],{"nctId":1135,"briefTitle":1136,"status":232,"phases":1137,"primaryCompletion":765,"completion":765,"start":1138,"enrollment":1139,"conditions":1140,"interventions":1142},"NCT01319357","Effects of Saxagliptin on Endothelial Function",[63],"2010-10",52,[1141],"Diabetes Mellitus Type 2",[1124],{"trials":1144,"activeCount":72},[],{"trials":1146,"activeCount":72},[],{"intervention":1148,"totalTrials":68,"cells":1149},"Linagliptin",{"EARLY_PHASE1":1150,"PHASE1":1152,"PHASE2":1154,"PHASE3":1156,"PHASE4":1169,"NA":1171},{"trials":1151,"activeCount":72},[],{"trials":1153,"activeCount":72},[],{"trials":1155,"activeCount":72},[],{"trials":1157,"activeCount":72},[1158],{"nctId":1159,"briefTitle":1160,"status":232,"phases":1161,"primaryCompletion":1162,"completion":1163,"start":1164,"enrollment":1165,"conditions":1166,"interventions":1168},"NCT01835678","Effects of Linagliptin on Renal Endothelium Function in Patients With Type 2 Diabetes.",[63],"2014-03","2014-04","2012-10",65,[1167],"Type 2-diabetes",[1148],{"trials":1170,"activeCount":72},[],{"trials":1172,"activeCount":72},[],{"intervention":1174,"totalTrials":68,"cells":1175},"Control group",{"EARLY_PHASE1":1176,"PHASE1":1178,"PHASE2":1180,"PHASE3":1182,"PHASE4":1193,"NA":1195},{"trials":1177,"activeCount":72},[],{"trials":1179,"activeCount":72},[],{"trials":1181,"activeCount":72},[],{"trials":1183,"activeCount":72},[1184],{"nctId":1185,"briefTitle":1186,"status":248,"phases":1187,"primaryCompletion":803,"completion":1188,"start":1189,"enrollment":1190,"conditions":1191,"interventions":1192},"NCT02779114","RETRO (REduction of Therapy in RA Patients in Ongoing Remission)",[63],"2018-06","2009-01",318,[659],[1174],{"trials":1194,"activeCount":72},[],{"trials":1196,"activeCount":72},[],{"intervention":1198,"totalTrials":68,"cells":1199},"Baricitinib",{"EARLY_PHASE1":1200,"PHASE1":1202,"PHASE2":1204,"PHASE3":1206,"PHASE4":1219,"NA":1221},{"trials":1201,"activeCount":72},[],{"trials":1203,"activeCount":72},[],{"trials":1205,"activeCount":72},[],{"trials":1207,"activeCount":72},[1208],{"nctId":1209,"briefTitle":1210,"status":248,"phases":1211,"primaryCompletion":1212,"completion":1212,"start":1213,"enrollment":1214,"conditions":1215,"interventions":1218},"NCT03701789","Effect of Baricitinib Treatment on Peripheral Bone in RA",[63],"2021-10-11","2018-09-11",15,[659,1216,1217],"Bone Density","Finger Joints",[1198],{"trials":1220,"activeCount":72},[],{"trials":1222,"activeCount":72},[],{"intervention":1224,"totalTrials":68,"cells":1225},"Dapagliflozin",{"EARLY_PHASE1":1226,"PHASE1":1228,"PHASE2":1230,"PHASE3":1232,"PHASE4":1241,"NA":1243},{"trials":1227,"activeCount":72},[],{"trials":1229,"activeCount":72},[],{"trials":1231,"activeCount":72},[],{"trials":1233,"activeCount":72},[1234],{"nctId":1235,"briefTitle":1236,"status":232,"phases":1237,"primaryCompletion":1238,"completion":1238,"start":1162,"enrollment":791,"conditions":1239,"interventions":1240},"NCT02383238","Effect of Dapagliflozin on Microvascular and Macrovascular Circulation and Total Body Sodium Content",[63],"2015-10",[1141],[1224],{"trials":1242,"activeCount":72},[],{"trials":1244,"activeCount":72},[],{"intervention":1246,"totalTrials":68,"cells":1247},"Pioglitazone",{"EARLY_PHASE1":1248,"PHASE1":1250,"PHASE2":1252,"PHASE3":1254,"PHASE4":1264,"NA":1266},{"trials":1249,"activeCount":72},[],{"trials":1251,"activeCount":72},[],{"trials":1253,"activeCount":72},[],{"trials":1255,"activeCount":72},[1256],{"nctId":1257,"briefTitle":1258,"status":232,"phases":1259,"primaryCompletion":1260,"completion":1261,"start":1260,"enrollment":289,"conditions":1262,"interventions":1263},"NCT00328393","Effect of Pioglitazone on Ambulatory Blood Pressure",[63],"2007-03","2011-01",[18,1141],[1246],{"trials":1265,"activeCount":72},[],{"trials":1267,"activeCount":72},[],{"intervention":1269,"totalTrials":68,"cells":1270},"spironolactone",{"EARLY_PHASE1":1271,"PHASE1":1273,"PHASE2":1275,"PHASE3":1277,"PHASE4":1287,"NA":1289},{"trials":1272,"activeCount":72},[],{"trials":1274,"activeCount":72},[],{"trials":1276,"activeCount":72},[],{"trials":1278,"activeCount":72},[1279],{"nctId":1280,"briefTitle":1281,"status":232,"phases":1282,"primaryCompletion":339,"completion":339,"start":1283,"enrollment":307,"conditions":1284,"interventions":1286},"NCT00865501","Importance of Aldosterone in the Pathogenesis of Hypertensive Heart Disease",[63],"2008-03",[1285],"Primary Hypertension",[1269],{"trials":1288,"activeCount":72},[],{"trials":1290,"activeCount":72},[],{"intervention":1292,"totalTrials":68,"cells":1293},"Paclitaxel\u002FCisplatin",{"EARLY_PHASE1":1294,"PHASE1":1296,"PHASE2":1298,"PHASE3":1300,"PHASE4":1314,"NA":1316},{"trials":1295,"activeCount":72},[],{"trials":1297,"activeCount":72},[],{"trials":1299,"activeCount":72},[],{"trials":1301,"activeCount":72},[1302],{"nctId":1303,"briefTitle":1304,"status":497,"phases":1305,"primaryCompletion":1306,"completion":1307,"start":1308,"enrollment":1309,"conditions":1310,"interventions":1312},"NCT01126216","Reduced Radiotherapy With Pac\u002FCis vs Standard Radiotherapy With 5-FU\u002FCis in Locally Advanced Head and Neck Cancer",[63],"2015-06","2019-06","2010-06",221,[1311],"Head and Neck Cancer",[1292,1313],"5-FU\u002FCisplatin",{"trials":1315,"activeCount":72},[],{"trials":1317,"activeCount":72},[],{"intervention":1313,"totalTrials":68,"cells":1319},{"EARLY_PHASE1":1320,"PHASE1":1322,"PHASE2":1324,"PHASE3":1326,"PHASE4":1332,"NA":1334},{"trials":1321,"activeCount":72},[],{"trials":1323,"activeCount":72},[],{"trials":1325,"activeCount":72},[],{"trials":1327,"activeCount":72},[1328],{"nctId":1303,"briefTitle":1304,"status":497,"phases":1329,"primaryCompletion":1306,"completion":1307,"start":1308,"enrollment":1309,"conditions":1330,"interventions":1331},[63],[1311],[1292,1313],{"trials":1333,"activeCount":72},[],{"trials":1335,"activeCount":72},[],{"intervention":1337,"totalTrials":68,"cells":1338},"Folic Acid",{"EARLY_PHASE1":1339,"PHASE1":1341,"PHASE2":1343,"PHASE3":1345,"PHASE4":1356,"NA":1358},{"trials":1340,"activeCount":72},[],{"trials":1342,"activeCount":72},[],{"trials":1344,"activeCount":72},[],{"trials":1346,"activeCount":72},[1347],{"nctId":1348,"briefTitle":1349,"status":232,"phases":1350,"primaryCompletion":1351,"completion":1351,"start":1352,"enrollment":613,"conditions":1353,"interventions":1355},"NCT00136188","Nitric Oxide (NO) Activity and Diabetic Nephropathy",[62,63],"2011-12","2009-08",[1354],"Diabetic Nephropathies",[1337],{"trials":1357,"activeCount":72},[],{"trials":1359,"activeCount":72},[],{"intervention":1361,"totalTrials":68,"cells":1362},"Empagliflozin",{"EARLY_PHASE1":1363,"PHASE1":1365,"PHASE2":1367,"PHASE3":1369,"PHASE4":1379,"NA":1381},{"trials":1364,"activeCount":72},[],{"trials":1366,"activeCount":72},[],{"trials":1368,"activeCount":72},[],{"trials":1370,"activeCount":72},[1371],{"nctId":1372,"briefTitle":1373,"status":232,"phases":1374,"primaryCompletion":1375,"completion":1071,"start":805,"enrollment":1376,"conditions":1377,"interventions":1378},"NCT02471963","Effect of Empagliflozin on Macrovascular and Microvascular Circulation and on Endothelium Function",[63],"2015-11",74,[1141],[1361],{"trials":1380,"activeCount":72},[],{"trials":1382,"activeCount":72},[],{"intervention":1384,"totalTrials":68,"cells":1385},"Telmisartan",{"EARLY_PHASE1":1386,"PHASE1":1388,"PHASE2":1390,"PHASE3":1392,"PHASE4":1401,"NA":1403},{"trials":1387,"activeCount":72},[],{"trials":1389,"activeCount":72},[],{"trials":1391,"activeCount":72},[],{"trials":1393,"activeCount":72},[1394],{"nctId":1395,"briefTitle":1396,"status":232,"phases":1397,"primaryCompletion":339,"completion":339,"start":1398,"enrollment":697,"conditions":1399,"interventions":1400},"NCT00452192","Telmisartan and Renal Perfusion in Patients With Metabolic Syndrome",[63],"2006-11",[22],[1384],{"trials":1402,"activeCount":72},[],{"trials":1404,"activeCount":72},[],{"intervention":1406,"totalTrials":68,"cells":1407},"Aliskiren",{"EARLY_PHASE1":1408,"PHASE1":1410,"PHASE2":1412,"PHASE3":1414,"PHASE4":1425,"NA":1427},{"trials":1409,"activeCount":72},[],{"trials":1411,"activeCount":72},[],{"trials":1413,"activeCount":72},[],{"trials":1415,"activeCount":72},[1416],{"nctId":1417,"briefTitle":1418,"status":232,"phases":1419,"primaryCompletion":500,"completion":500,"start":1420,"enrollment":1421,"conditions":1422,"interventions":1424},"NCT01318395","Aliskiren on Retinal Vasculature Treatment Study",[63],"2010-05",56,[1423],"Arterial Hypertension",[1406],{"trials":1426,"activeCount":72},[],{"trials":1428,"activeCount":72},[],{"intervention":1430,"totalTrials":68,"cells":1431},"amlodipine 10 mg",{"EARLY_PHASE1":1432,"PHASE1":1434,"PHASE2":1436,"PHASE3":1438,"PHASE4":1450,"NA":1452},{"trials":1433,"activeCount":72},[],{"trials":1435,"activeCount":72},[],{"trials":1437,"activeCount":72},[],{"trials":1439,"activeCount":72},[1440],{"nctId":1441,"briefTitle":1442,"status":232,"phases":1443,"primaryCompletion":501,"completion":501,"start":1444,"enrollment":613,"conditions":1445,"interventions":1446},"NCT00627952","A Study to Evaluate the Effects of Manidipine Versus Amlodipine and the Combination of Manidipine Plus Delapril Versus Amlodipine Plus Delapril on Intraglomerular Pressure in Hypertensive Patients",[63],"2007-11",[18],[1430,1447,1448,1449],"manidipine 20 mg","amlodipine 5 mg + delapril 30 mg","manidipine 10 mg + delapril 30 mg",{"trials":1451,"activeCount":72},[],{"trials":1453,"activeCount":72},[],{"intervention":1447,"totalTrials":68,"cells":1455},{"EARLY_PHASE1":1456,"PHASE1":1458,"PHASE2":1460,"PHASE3":1462,"PHASE4":1468,"NA":1470},{"trials":1457,"activeCount":72},[],{"trials":1459,"activeCount":72},[],{"trials":1461,"activeCount":72},[],{"trials":1463,"activeCount":72},[1464],{"nctId":1441,"briefTitle":1442,"status":232,"phases":1465,"primaryCompletion":501,"completion":501,"start":1444,"enrollment":613,"conditions":1466,"interventions":1467},[63],[18],[1430,1447,1448,1449],{"trials":1469,"activeCount":72},[],{"trials":1471,"activeCount":72},[],{"intervention":1448,"totalTrials":68,"cells":1473},{"EARLY_PHASE1":1474,"PHASE1":1476,"PHASE2":1478,"PHASE3":1480,"PHASE4":1486,"NA":1488},{"trials":1475,"activeCount":72},[],{"trials":1477,"activeCount":72},[],{"trials":1479,"activeCount":72},[],{"trials":1481,"activeCount":72},[1482],{"nctId":1441,"briefTitle":1442,"status":232,"phases":1483,"primaryCompletion":501,"completion":501,"start":1444,"enrollment":613,"conditions":1484,"interventions":1485},[63],[18],[1430,1447,1448,1449],{"trials":1487,"activeCount":72},[],{"trials":1489,"activeCount":72},[],{"intervention":1449,"totalTrials":68,"cells":1491},{"EARLY_PHASE1":1492,"PHASE1":1494,"PHASE2":1496,"PHASE3":1498,"PHASE4":1504,"NA":1506},{"trials":1493,"activeCount":72},[],{"trials":1495,"activeCount":72},[],{"trials":1497,"activeCount":72},[],{"trials":1499,"activeCount":72},[1500],{"nctId":1441,"briefTitle":1442,"status":232,"phases":1501,"primaryCompletion":501,"completion":501,"start":1444,"enrollment":613,"conditions":1502,"interventions":1503},[63],[18],[1430,1447,1448,1449],{"trials":1505,"activeCount":72},[],{"trials":1507,"activeCount":72},[],{"intervention":1509,"totalTrials":68,"cells":1510},"Losartan",{"EARLY_PHASE1":1511,"PHASE1":1513,"PHASE2":1515,"PHASE3":1517,"PHASE4":1528,"NA":1530},{"trials":1512,"activeCount":72},[],{"trials":1514,"activeCount":72},[],{"trials":1516,"activeCount":72},[],{"trials":1518,"activeCount":72},[1519],{"nctId":1520,"briefTitle":1521,"status":453,"phases":1522,"primaryCompletion":1523,"completion":1523,"start":1524,"enrollment":72,"conditions":1525,"interventions":1526},"NCT00152633","Effect of Losartan on Retinal Endothelial Function in Patients With Essential Hypertension",[62,63],"2006-01","2005-09",[18],[1509,1527,1509],"Metoprolol",{"trials":1529,"activeCount":72},[],{"trials":1531,"activeCount":72},[],{"intervention":1527,"totalTrials":68,"cells":1533},{"EARLY_PHASE1":1534,"PHASE1":1536,"PHASE2":1538,"PHASE3":1540,"PHASE4":1546,"NA":1548},{"trials":1535,"activeCount":72},[],{"trials":1537,"activeCount":72},[],{"trials":1539,"activeCount":72},[],{"trials":1541,"activeCount":72},[1542],{"nctId":1520,"briefTitle":1521,"status":453,"phases":1543,"primaryCompletion":1523,"completion":1523,"start":1524,"enrollment":72,"conditions":1544,"interventions":1545},[62,63],[18],[1509,1527,1509],{"trials":1547,"activeCount":72},[],{"trials":1549,"activeCount":72},[],{"intervention":1551,"totalTrials":68,"cells":1552},"Induction chemotherapy with gemcitabine or FOLFIRINOX",{"EARLY_PHASE1":1553,"PHASE1":1555,"PHASE2":1557,"PHASE3":1559,"PHASE4":1574,"NA":1576},{"trials":1554,"activeCount":72},[],{"trials":1556,"activeCount":72},[],{"trials":1558,"activeCount":72},[],{"trials":1560,"activeCount":72},[1561],{"nctId":1562,"briefTitle":1563,"status":232,"phases":1564,"primaryCompletion":1565,"completion":1566,"start":1567,"enrollment":1568,"conditions":1569,"interventions":1571},"NCT01827553","Pancreatic Carcinoma: Chemoradiation Compared With Chemotherapy Alone After Induction Chemotherapy",[63],"2021-02-02","2023-11-08","2013-04-04",830,[1570],"Pancreatic Cancer",[1551,1572,1573],"Chemotherapy, gemcitabine","Chemotherapy with gemcitabine or FOLFIRINOX according to induction chemotherapy",{"trials":1575,"activeCount":72},[],{"trials":1577,"activeCount":72},[],{"intervention":1572,"totalTrials":68,"cells":1579},{"EARLY_PHASE1":1580,"PHASE1":1582,"PHASE2":1584,"PHASE3":1586,"PHASE4":1592,"NA":1594},{"trials":1581,"activeCount":72},[],{"trials":1583,"activeCount":72},[],{"trials":1585,"activeCount":72},[],{"trials":1587,"activeCount":72},[1588],{"nctId":1562,"briefTitle":1563,"status":232,"phases":1589,"primaryCompletion":1565,"completion":1566,"start":1567,"enrollment":1568,"conditions":1590,"interventions":1591},[63],[1570],[1551,1572,1573],{"trials":1593,"activeCount":72},[],{"trials":1595,"activeCount":72},[],{"intervention":1573,"totalTrials":68,"cells":1597},{"EARLY_PHASE1":1598,"PHASE1":1600,"PHASE2":1602,"PHASE3":1604,"PHASE4":1610,"NA":1612},{"trials":1599,"activeCount":72},[],{"trials":1601,"activeCount":72},[],{"trials":1603,"activeCount":72},[],{"trials":1605,"activeCount":72},[1606],{"nctId":1562,"briefTitle":1563,"status":232,"phases":1607,"primaryCompletion":1565,"completion":1566,"start":1567,"enrollment":1568,"conditions":1608,"interventions":1609},[63],[1570],[1551,1572,1573],{"trials":1611,"activeCount":72},[],{"trials":1613,"activeCount":72},[],{"intervention":1615,"totalTrials":68,"cells":1616},"Finerenone 20 MG Oral",{"EARLY_PHASE1":1617,"PHASE1":1619,"PHASE2":1621,"PHASE3":1623,"PHASE4":1635,"NA":1637},{"trials":1618,"activeCount":72},[],{"trials":1620,"activeCount":72},[],{"trials":1622,"activeCount":72},[],{"trials":1624,"activeCount":72},[1625],{"nctId":1626,"briefTitle":1627,"status":232,"phases":1628,"primaryCompletion":1629,"completion":1629,"start":1630,"enrollment":1631,"conditions":1632,"interventions":1634},"NCT06244758","Finerenone and Renal Oxidative Stress",[63],"2025-11-25","2024-01-18",91,[1633],"Type2diabetes",[1615],{"trials":1636,"activeCount":72},[],{"trials":1638,"activeCount":72},[],{"intervention":1640,"totalTrials":68,"cells":1641},"Irbesartan",{"EARLY_PHASE1":1642,"PHASE1":1644,"PHASE2":1646,"PHASE3":1648,"PHASE4":1657,"NA":1659},{"trials":1643,"activeCount":72},[],{"trials":1645,"activeCount":72},[],{"trials":1647,"activeCount":72},[],{"trials":1649,"activeCount":72},[1650],{"nctId":1651,"briefTitle":1652,"status":453,"phases":1653,"primaryCompletion":339,"completion":339,"start":456,"enrollment":72,"conditions":1654,"interventions":1656},"NCT00152698","Effect of Irbesartan on Endothelial Function of the Retinal Vasculature in Patients With Hypercholesterolemia",[63],[1655],"Hypercholesterolemia",[1640],{"trials":1658,"activeCount":72},[],{"trials":1660,"activeCount":72},[],{"intervention":810,"totalTrials":68,"cells":1662},{"EARLY_PHASE1":1663,"PHASE1":1665,"PHASE2":1667,"PHASE3":1669,"PHASE4":1675,"NA":1677},{"trials":1664,"activeCount":72},[],{"trials":1666,"activeCount":72},[],{"trials":1668,"activeCount":72},[],{"trials":1670,"activeCount":72},[1671],{"nctId":800,"briefTitle":801,"status":248,"phases":1672,"primaryCompletion":803,"completion":804,"start":805,"enrollment":806,"conditions":1673,"interventions":1674},[63],[808],[810,777],{"trials":1676,"activeCount":72},[],{"trials":1678,"activeCount":72},[],{"intervention":1680,"totalTrials":68,"cells":1681},"Clonidine",{"EARLY_PHASE1":1682,"PHASE1":1684,"PHASE2":1686,"PHASE3":1688,"PHASE4":1702,"NA":1704},{"trials":1683,"activeCount":72},[],{"trials":1685,"activeCount":72},[],{"trials":1687,"activeCount":72},[],{"trials":1689,"activeCount":72},[1690],{"nctId":1691,"briefTitle":1692,"status":497,"phases":1693,"primaryCompletion":1694,"completion":1695,"start":1696,"enrollment":1697,"conditions":1698,"interventions":1700},"NCT02509273","Efficacy, Safety and Pharmacokinetic Study of Intravenous Clonidine Versus Midazolam for Sedation in Paediatric Patients",[63],"2018-10","2018-10-22","2016-05",28,[1699],"Sedation in Intensive Care",[1680,1701],"Midazolam",{"trials":1703,"activeCount":72},[],{"trials":1705,"activeCount":72},[],{"intervention":1701,"totalTrials":68,"cells":1707},{"EARLY_PHASE1":1708,"PHASE1":1710,"PHASE2":1712,"PHASE3":1714,"PHASE4":1720,"NA":1722},{"trials":1709,"activeCount":72},[],{"trials":1711,"activeCount":72},[],{"trials":1713,"activeCount":72},[],{"trials":1715,"activeCount":72},[1716],{"nctId":1691,"briefTitle":1692,"status":497,"phases":1717,"primaryCompletion":1694,"completion":1695,"start":1696,"enrollment":1697,"conditions":1718,"interventions":1719},[63],[1699],[1680,1701],{"trials":1721,"activeCount":72},[],{"trials":1723,"activeCount":72},[],{"intervention":1725,"totalTrials":68,"cells":1726},"Ripasudil eye drops",{"EARLY_PHASE1":1727,"PHASE1":1729,"PHASE2":1731,"PHASE3":1748,"PHASE4":1750,"NA":1752},{"trials":1728,"activeCount":72},[],{"trials":1730,"activeCount":72},[],{"trials":1732,"activeCount":72},[1733],{"nctId":1734,"briefTitle":1735,"status":248,"phases":1736,"primaryCompletion":1737,"completion":1737,"start":1738,"enrollment":1739,"conditions":1740,"interventions":1746},"NCT03575130","Ripasudil 0.4% Eye Drops in Fuchs Endothelial Corneal Dystrophy",[62],"2018-12-31","2018-06-05",21,[1741,1742,1743,1744,1745],"Fuchs' Endothelial Dystrophy","Fuchs Dystrophy","Corneal Endothelial Dystrophy","Corneal Endothelial Cell Loss","Cornea Guttata",[1725,1747],"Optive eye drops",{"trials":1749,"activeCount":72},[],{"trials":1751,"activeCount":72},[],{"trials":1753,"activeCount":72},[],{"intervention":1747,"totalTrials":68,"cells":1755},{"EARLY_PHASE1":1756,"PHASE1":1758,"PHASE2":1760,"PHASE3":1766,"PHASE4":1768,"NA":1770},{"trials":1757,"activeCount":72},[],{"trials":1759,"activeCount":72},[],{"trials":1761,"activeCount":72},[1762],{"nctId":1734,"briefTitle":1735,"status":248,"phases":1763,"primaryCompletion":1737,"completion":1737,"start":1738,"enrollment":1739,"conditions":1764,"interventions":1765},[62],[1741,1742,1743,1744,1745],[1725,1747],{"trials":1767,"activeCount":72},[],{"trials":1769,"activeCount":72},[],{"trials":1771,"activeCount":72},[],{"intervention":1773,"totalTrials":68,"cells":1774},"somatropin",{"EARLY_PHASE1":1775,"PHASE1":1777,"PHASE2":1779,"PHASE3":1791,"PHASE4":1793,"NA":1795},{"trials":1776,"activeCount":72},[],{"trials":1778,"activeCount":72},[],{"trials":1780,"activeCount":72},[1781],{"nctId":1782,"briefTitle":1783,"status":232,"phases":1784,"primaryCompletion":1785,"completion":1786,"start":1787,"enrollment":1116,"conditions":1788,"interventions":1790},"NCT00488124","Growth Response in Short Children Suffering From a Disease With Growth Retardation and Treated With Somatropin",[62],"2011-02","2011-03","2005-11",[1789],"Idiopathic Short Stature",[1773],{"trials":1792,"activeCount":72},[],{"trials":1794,"activeCount":72},[],{"trials":1796,"activeCount":72},[],{"intervention":1798,"totalTrials":68,"cells":1799},"Empagliflozin 10mg",{"EARLY_PHASE1":1800,"PHASE1":1802,"PHASE2":1804,"PHASE3":1817,"PHASE4":1819,"NA":1821},{"trials":1801,"activeCount":72},[],{"trials":1803,"activeCount":72},[],{"trials":1805,"activeCount":72},[1806],{"nctId":1807,"briefTitle":1808,"status":232,"phases":1809,"primaryCompletion":1810,"completion":1811,"start":1812,"enrollment":1813,"conditions":1814,"interventions":1816},"NCT03128528","Analysing the Effect of Empagliflozin on Reduction of Tissue Sodium Content in Patients With Chronic Heart Failure",[62],"2020-01-31","2020-04-30","2017-07-01",84,[1815],"Chronic Heart Failure",[1798],{"trials":1818,"activeCount":72},[],{"trials":1820,"activeCount":72},[],{"trials":1822,"activeCount":72},[],{"intervention":1824,"totalTrials":68,"cells":1825},"Deferasirox",{"EARLY_PHASE1":1826,"PHASE1":1828,"PHASE2":1830,"PHASE3":1841,"PHASE4":1843,"NA":1845},{"trials":1827,"activeCount":72},[],{"trials":1829,"activeCount":72},[],{"trials":1831,"activeCount":72},[1832],{"nctId":1833,"briefTitle":1834,"status":497,"phases":1835,"primaryCompletion":1836,"completion":1836,"start":1837,"enrollment":289,"conditions":1838,"interventions":1840},"NCT01058369","Exjade-Early-Trial",[62],"2013-01","2010-04",[1839],"Myelodysplastic Syndromes",[1824],{"trials":1842,"activeCount":72},[],{"trials":1844,"activeCount":72},[],{"trials":1846,"activeCount":72},[],{"intervention":1848,"totalTrials":68,"cells":1849},"FITC-Adalimumab",{"EARLY_PHASE1":1850,"PHASE1":1852,"PHASE2":1854,"PHASE3":1864,"PHASE4":1866,"NA":1868},{"trials":1851,"activeCount":72},[],{"trials":1853,"activeCount":72},[],{"trials":1855,"activeCount":72},[1856],{"nctId":1857,"briefTitle":1858,"status":232,"phases":1859,"primaryCompletion":1860,"completion":1860,"start":1261,"enrollment":1861,"conditions":1862,"interventions":1863},"NCT01275508","Safety and Tolerability of FITC-Adalimumab Administration During Confocal Laser Endomicroscopy of the Gut",[61,62],"2012-04",25,[27],[1848],{"trials":1865,"activeCount":72},[],{"trials":1867,"activeCount":72},[],{"trials":1869,"activeCount":72},[],{"intervention":1871,"totalTrials":68,"cells":1872},"A",{"EARLY_PHASE1":1873,"PHASE1":1875,"PHASE2":1877,"PHASE3":1890,"PHASE4":1892,"NA":1894},{"trials":1874,"activeCount":72},[],{"trials":1876,"activeCount":72},[],{"trials":1878,"activeCount":72},[1879],{"nctId":1880,"briefTitle":1881,"status":497,"phases":1882,"primaryCompletion":1883,"completion":1883,"start":1884,"enrollment":1885,"conditions":1886,"interventions":1888},"NCT03386357","Radiotherapy With Pembrolizumab in Metastatic Head and Neck Squamous Cell Carcinoma (HNSCC)",[62],"2024-10-01","2018-07-20",115,[1887],"Head and Neck Squamous Cell Carcinoma",[1871,1889],"B",{"trials":1891,"activeCount":72},[],{"trials":1893,"activeCount":72},[],{"trials":1895,"activeCount":72},[],{"intervention":1889,"totalTrials":68,"cells":1897},{"EARLY_PHASE1":1898,"PHASE1":1900,"PHASE2":1902,"PHASE3":1908,"PHASE4":1910,"NA":1912},{"trials":1899,"activeCount":72},[],{"trials":1901,"activeCount":72},[],{"trials":1903,"activeCount":72},[1904],{"nctId":1880,"briefTitle":1881,"status":497,"phases":1905,"primaryCompletion":1883,"completion":1883,"start":1884,"enrollment":1885,"conditions":1906,"interventions":1907},[62],[1887],[1871,1889],{"trials":1909,"activeCount":72},[],{"trials":1911,"activeCount":72},[],{"trials":1913,"activeCount":72},[],{"intervention":1915,"totalTrials":68,"cells":1916},"COVID-19 convalescent plasma",{"EARLY_PHASE1":1917,"PHASE1":1919,"PHASE2":1921,"PHASE3":1933,"PHASE4":1935,"NA":1937},{"trials":1918,"activeCount":72},[],{"trials":1920,"activeCount":72},[],{"trials":1922,"activeCount":72},[1923],{"nctId":1924,"briefTitle":1925,"status":248,"phases":1926,"primaryCompletion":1927,"completion":1927,"start":1928,"enrollment":1929,"conditions":1930,"interventions":1932},"NCT04712344","Assessment of Efficacy and Safety of Therapy With COVID-19 Convalescent Plasma in Subjects With Severe COVID-19 (IPCO)",[62],"2021-09","2021-01-18",58,[1931],"Severe COVID-19",[1915],{"trials":1934,"activeCount":72},[],{"trials":1936,"activeCount":72},[],{"trials":1938,"activeCount":72},[],{"intervention":1940,"totalTrials":68,"cells":1941},"Dacarbazine",{"EARLY_PHASE1":1942,"PHASE1":1944,"PHASE2":1946,"PHASE3":1957,"PHASE4":1959,"NA":1961},{"trials":1943,"activeCount":72},[],{"trials":1945,"activeCount":72},[],{"trials":1947,"activeCount":72},[1948],{"nctId":1949,"briefTitle":1950,"status":232,"phases":1951,"primaryCompletion":106,"completion":106,"start":1952,"enrollment":1953,"conditions":1954,"interventions":1956},"NCT04225390","Preconditioning of Tumor, Tumor Microenvironment and the Immune System to Immunotherapy",[62],"2020-01-13",38,[1955],"Immunotherapy",[1940],{"trials":1958,"activeCount":72},[],{"trials":1960,"activeCount":72},[],{"trials":1962,"activeCount":72},[],{"intervention":1964,"totalTrials":68,"cells":1965},"CMV\u002FEBV specific T-cell",{"EARLY_PHASE1":1966,"PHASE1":1968,"PHASE2":1970,"PHASE3":1982,"PHASE4":1984,"NA":1986},{"trials":1967,"activeCount":72},[],{"trials":1969,"activeCount":72},[],{"trials":1971,"activeCount":72},[1972],{"nctId":1973,"briefTitle":1974,"status":232,"phases":1975,"primaryCompletion":1976,"completion":1977,"start":1978,"enrollment":307,"conditions":1979,"interventions":1981},"NCT02227641","Preventative\u002FPreemptive Adoptive Transfer of Peptide Stimulated CMV\u002FEBV Specific T-cells in Patients After Allogeneic Stem Cell Transplantation",[61,62],"2016-10","2017-03","2014-10",[1980],"Patients Undergoing Allogeneic Stem Cell Transplantation",[1964],{"trials":1983,"activeCount":72},[],{"trials":1985,"activeCount":72},[],{"trials":1987,"activeCount":72},[],{"intervention":795,"totalTrials":68,"cells":1989},{"EARLY_PHASE1":1990,"PHASE1":1992,"PHASE2":1994,"PHASE3":2000,"PHASE4":2002,"NA":2004},{"trials":1991,"activeCount":72},[],{"trials":1993,"activeCount":72},[],{"trials":1995,"activeCount":72},[1996],{"nctId":786,"briefTitle":787,"status":248,"phases":1997,"primaryCompletion":789,"completion":790,"start":636,"enrollment":791,"conditions":1998,"interventions":1999},[61,62],[793],[777,795,796],{"trials":2001,"activeCount":72},[],{"trials":2003,"activeCount":72},[],{"trials":2005,"activeCount":72},[],{"intervention":796,"totalTrials":68,"cells":2007},{"EARLY_PHASE1":2008,"PHASE1":2010,"PHASE2":2012,"PHASE3":2018,"PHASE4":2020,"NA":2022},{"trials":2009,"activeCount":72},[],{"trials":2011,"activeCount":72},[],{"trials":2013,"activeCount":72},[2014],{"nctId":786,"briefTitle":787,"status":248,"phases":2015,"primaryCompletion":789,"completion":790,"start":636,"enrollment":791,"conditions":2016,"interventions":2017},[61,62],[793],[777,795,796],{"trials":2019,"activeCount":72},[],{"trials":2021,"activeCount":72},[],{"trials":2023,"activeCount":72},[],{"intervention":2025,"totalTrials":68,"cells":2026},"Rosuvastatin",{"EARLY_PHASE1":2027,"PHASE1":2029,"PHASE2":2031,"PHASE3":2040,"PHASE4":2042,"NA":2044},{"trials":2028,"activeCount":72},[],{"trials":2030,"activeCount":72},[],{"trials":2032,"activeCount":72},[2033],{"nctId":2034,"briefTitle":2035,"status":232,"phases":2036,"completion":2037,"enrollment":107,"conditions":2038,"interventions":2039},"NCT00160745","Rosuvastatin and Renal Endothelial Function",[62],"2006-09",[1655],[2025],{"trials":2041,"activeCount":72},[],{"trials":2043,"activeCount":72},[],{"trials":2045,"activeCount":72},[],{"intervention":2047,"totalTrials":68,"cells":2048},"ethinyl estradiol 0.03mg and dienogest 2 mg",{"EARLY_PHASE1":2049,"PHASE1":2051,"PHASE2":2053,"PHASE3":2065,"PHASE4":2067,"NA":2069},{"trials":2050,"activeCount":72},[],{"trials":2052,"activeCount":72},[],{"trials":2054,"activeCount":72},[2055],{"nctId":2056,"briefTitle":2057,"status":497,"phases":2058,"primaryCompletion":2059,"completion":2059,"start":2060,"enrollment":2061,"conditions":2062,"interventions":2064},"NCT03172533","Estrogen Replacement in Anorexia Nervosa",[62],"2019-01-15","2016-03-15",11,[2063],"Anorexia Nervosa",[2047],{"trials":2066,"activeCount":72},[],{"trials":2068,"activeCount":72},[],{"trials":2070,"activeCount":72},[],{"intervention":2072,"totalTrials":68,"cells":2073},"Etoricoxib 60 mg",{"EARLY_PHASE1":2074,"PHASE1":2076,"PHASE2":2078,"PHASE3":2090,"PHASE4":2092,"NA":2094},{"trials":2075,"activeCount":72},[],{"trials":2077,"activeCount":72},[],{"trials":2079,"activeCount":72},[2080],{"nctId":2081,"briefTitle":2082,"status":497,"phases":2083,"primaryCompletion":2084,"completion":2085,"start":1115,"enrollment":2086,"conditions":2087,"interventions":2089},"NCT00746720","Modulation of the Surgical Inflammatory Response by Etoricoxib",[62],"2009-07","2010-12",23,[639,2088,309],"Osteoarthritis, Hip",[2072,2072],{"trials":2091,"activeCount":72},[],{"trials":2093,"activeCount":72},[],{"trials":2095,"activeCount":72},[],{"intervention":2097,"totalTrials":68,"cells":2098},"Durvalumab + Tremelimumab + RT",{"EARLY_PHASE1":2099,"PHASE1":2101,"PHASE2":2103,"PHASE3":2115,"PHASE4":2117,"NA":2119},{"trials":2100,"activeCount":72},[],{"trials":2102,"activeCount":72},[],{"trials":2104,"activeCount":72},[2105],{"nctId":2106,"briefTitle":2107,"status":232,"phases":2108,"primaryCompletion":2109,"completion":2110,"start":2111,"enrollment":1116,"conditions":2112,"interventions":2114},"NCT03426657","Radiotherapy With Double Checkpoint Blockade of Locally Advanced HNSCC",[62],"2021-09-16","2024-02-29","2018-09-20",[2113],"Locally Advanced Head and Neck Squamous Cell Carcinoma",[2097],{"trials":2116,"activeCount":72},[],{"trials":2118,"activeCount":72},[],{"trials":2120,"activeCount":72},[],{"intervention":2122,"totalTrials":68,"cells":2123},"allogeneic donor derived B-lymphocytes",{"EARLY_PHASE1":2124,"PHASE1":2126,"PHASE2":2128,"PHASE3":2145,"PHASE4":2147,"NA":2149},{"trials":2125,"activeCount":72},[],{"trials":2127,"activeCount":72},[],{"trials":2129,"activeCount":72},[2130],{"nctId":2131,"briefTitle":2132,"status":248,"phases":2133,"primaryCompletion":1070,"completion":1070,"start":2134,"enrollment":1214,"conditions":2135,"interventions":2144},"NCT02007811","Open-label Clinical Trial to Investigate the Safety and Tolerability of Allogeneic B-cell Concentrates for Immune Reconstitution After Allogeneic Stem Cell Transplantation Measured as Response to a Antedated Single Vaccination",[61,62],"2013-11",[2136,2137,2138,2139,2140,2141,2142,2143],"Acute Myeloid Leukemia","Acute Lymphoblastic Leukemia","Chronic Myeloid Leukemia","Non Hodgkin's Lymphoma","Hodgkin's Disease","Myelodysplastic Syndrome","Multiple Myeloma","Aplastic Anemia",[2122],{"trials":2146,"activeCount":72},[],{"trials":2148,"activeCount":72},[],{"trials":2150,"activeCount":72},[],{"intervention":2152,"totalTrials":68,"cells":2153},"Sorafenib + LBH589",{"EARLY_PHASE1":2154,"PHASE1":2156,"PHASE2":2165,"PHASE3":2167,"PHASE4":2169,"NA":2171},{"trials":2155,"activeCount":72},[],{"trials":2157,"activeCount":72},[2158],{"nctId":2159,"briefTitle":2160,"status":497,"phases":2161,"primaryCompletion":2085,"completion":2085,"start":1189,"enrollment":289,"conditions":2162,"interventions":2164},"NCT00823290","Sorafenib and LBH589 in Hepatocellular Carcinoma (HCC)",[61],[2163],"Hepatocellular Carcinoma",[2152],{"trials":2166,"activeCount":72},[],{"trials":2168,"activeCount":72},[],{"trials":2170,"activeCount":72},[],{"trials":2172,"activeCount":72},[],{"intervention":2174,"totalTrials":68,"cells":2175},"Regulatory T cells",{"EARLY_PHASE1":2176,"PHASE1":2178,"PHASE2":2190,"PHASE3":2192,"PHASE4":2194,"NA":2196},{"trials":2177,"activeCount":72},[],{"trials":2179,"activeCount":72},[2180],{"nctId":2181,"briefTitle":2182,"status":232,"phases":2183,"primaryCompletion":2184,"completion":2185,"start":2186,"enrollment":2061,"conditions":2187,"interventions":2189},"NCT04691232","Autologous Ex Vivo Expanded Regulatory T Cells in Ulcerative Colitis",[61],"2023-04-12","2023-05-22","2021-02-22",[15,2188],"Autoimmune Diseases",[2174],{"trials":2191,"activeCount":72},[],{"trials":2193,"activeCount":72},[],{"trials":2195,"activeCount":72},[],{"trials":2197,"activeCount":72},[],{"intervention":2199,"totalTrials":68,"cells":2200},"Drug treatment of Primary Aldosteronism",{"EARLY_PHASE1":2201,"PHASE1":2203,"PHASE2":2205,"PHASE3":2207,"PHASE4":2209,"NA":2211},{"trials":2202,"activeCount":72},[],{"trials":2204,"activeCount":72},[],{"trials":2206,"activeCount":72},[],{"trials":2208,"activeCount":72},[],{"trials":2210,"activeCount":72},[],{"trials":2212,"activeCount":72},[2213],{"nctId":2214,"briefTitle":2215,"status":232,"phases":2216,"primaryCompletion":2217,"completion":2217,"start":2218,"enrollment":1739,"conditions":2219,"interventions":2222},"NCT04251780","Tissue K+ in Primary Hyperaldosteronism",[],"2024-04-24","2018-01-01",[2220,2221],"Primary Hyperaldosteronism","Electrolyte Disturbance",[2199],{"intervention":2224,"totalTrials":68,"cells":2225},"Telmisartan 80 mg\u002Fd",{"EARLY_PHASE1":2226,"PHASE1":2228,"PHASE2":2230,"PHASE3":2232,"PHASE4":2234,"NA":2236},{"trials":2227,"activeCount":72},[],{"trials":2229,"activeCount":72},[],{"trials":2231,"activeCount":72},[],{"trials":2233,"activeCount":72},[],{"trials":2235,"activeCount":72},[],{"trials":2237,"activeCount":72},[2238],{"nctId":2239,"briefTitle":2240,"status":232,"phases":2241,"primaryCompletion":2242,"completion":2242,"start":2243,"enrollment":2244,"conditions":2245,"interventions":2247},"NCT00905528","TRENDY Follow-up: Study on Endothelial Function in Subjects With Type 2 Diabetes Mellitus",[],"2004-12","2002-01",69,[2246],"Type 2 Diabetes Mellitus",[2224,2248],"Ramipril 10 mg\u002Fd",{"intervention":2248,"totalTrials":68,"cells":2250},{"EARLY_PHASE1":2251,"PHASE1":2253,"PHASE2":2255,"PHASE3":2257,"PHASE4":2259,"NA":2261},{"trials":2252,"activeCount":72},[],{"trials":2254,"activeCount":72},[],{"trials":2256,"activeCount":72},[],{"trials":2258,"activeCount":72},[],{"trials":2260,"activeCount":72},[],{"trials":2262,"activeCount":72},[2263],{"nctId":2239,"briefTitle":2240,"status":232,"phases":2264,"primaryCompletion":2242,"completion":2242,"start":2243,"enrollment":2244,"conditions":2265,"interventions":2266},[],[2246],[2224,2248],{"intervention":2268,"totalTrials":68,"cells":2269},"Elexacaftor \u002F Ivacaftor \u002F Tezacaftor",{"EARLY_PHASE1":2270,"PHASE1":2272,"PHASE2":2274,"PHASE3":2276,"PHASE4":2278,"NA":2280},{"trials":2271,"activeCount":72},[],{"trials":2273,"activeCount":72},[],{"trials":2275,"activeCount":72},[],{"trials":2277,"activeCount":72},[],{"trials":2279,"activeCount":72},[],{"trials":2281,"activeCount":72},[2282],{"nctId":2283,"briefTitle":2284,"status":248,"phases":2285,"primaryCompletion":2286,"completion":2286,"start":2287,"enrollment":2288,"conditions":2289,"interventions":2291},"NCT05576324","Effect of the CFTR-modulating Triple Therapy Elexacaftor - Tezacaftor - Ivacaftor",[],"2023-10-18","2020-12-30",130,[2290],"Cystic Fibrosis",[2268],{"intervention":2293,"totalTrials":68,"cells":2294},"thrombolysis therapy",{"EARLY_PHASE1":2295,"PHASE1":2297,"PHASE2":2299,"PHASE3":2301,"PHASE4":2303,"NA":2305},{"trials":2296,"activeCount":72},[],{"trials":2298,"activeCount":72},[],{"trials":2300,"activeCount":72},[],{"trials":2302,"activeCount":72},[],{"trials":2304,"activeCount":72},[],{"trials":2306,"activeCount":72},[2307],{"nctId":2308,"briefTitle":2309,"status":232,"phases":2310,"primaryCompletion":2311,"completion":2312,"start":2313,"enrollment":2314,"conditions":2315,"interventions":2317},"NCT04357899","Stroke Research Consortium in Northern Bavaria (STAMINA)",[],"2019-12-31","2020-03-31","2006-01-01",3769,[2316],"Ischemic Stroke",[2293,2318],"initiation of antiplatelets, oral anticoagulation and lipid lowering drugs for secondary prevention",{"intervention":2318,"totalTrials":68,"cells":2320},{"EARLY_PHASE1":2321,"PHASE1":2323,"PHASE2":2325,"PHASE3":2327,"PHASE4":2329,"NA":2331},{"trials":2322,"activeCount":72},[],{"trials":2324,"activeCount":72},[],{"trials":2326,"activeCount":72},[],{"trials":2328,"activeCount":72},[],{"trials":2330,"activeCount":72},[],{"trials":2332,"activeCount":72},[2333],{"nctId":2308,"briefTitle":2309,"status":232,"phases":2334,"primaryCompletion":2311,"completion":2312,"start":2313,"enrollment":2314,"conditions":2335,"interventions":2336},[],[2316],[2293,2318],{"intervention":2338,"totalTrials":68,"cells":2339},"Genetic based analysis of identifying predictors of blood pressure in patients after renal denervation",{"EARLY_PHASE1":2340,"PHASE1":2342,"PHASE2":2344,"PHASE3":2346,"PHASE4":2348,"NA":2350},{"trials":2341,"activeCount":72},[],{"trials":2343,"activeCount":72},[],{"trials":2345,"activeCount":72},[],{"trials":2347,"activeCount":72},[],{"trials":2349,"activeCount":72},[],{"trials":2351,"activeCount":72},[2352],{"nctId":2353,"briefTitle":2354,"status":232,"phases":2355,"primaryCompletion":2356,"completion":2357,"start":2358,"enrollment":2359,"conditions":2360,"interventions":2363},"NCT04321044","Genetic Based Analysis in Hypertensive Patients",[65],"2020-07-23","2023-12-31","2019-01-01",300,[18,2361,2362],"Renal Denervation","Genetic Predisposition",[2338],{"intervention":2365,"totalTrials":68,"cells":2366},"Topical Steroids",{"EARLY_PHASE1":2367,"PHASE1":2369,"PHASE2":2371,"PHASE3":2373,"PHASE4":2375,"NA":2377},{"trials":2368,"activeCount":72},[],{"trials":2370,"activeCount":72},[],{"trials":2372,"activeCount":72},[],{"trials":2374,"activeCount":72},[],{"trials":2376,"activeCount":72},[],{"trials":2378,"activeCount":72},[2379],{"nctId":2380,"briefTitle":2381,"status":232,"phases":2382,"completion":1260,"start":2383,"enrollment":2384,"conditions":2385,"interventions":2387},"NCT00450996","Analysis of a Beneficial Effect of Prolonges Topical Steroid Treatment After Low-risk Penetrating Keratoplasty",[65],"1999-01",400,[2386],"Graft Rejection",[2365],{"intervention":2389,"totalTrials":68,"cells":2390},"Naja-comp.",{"EARLY_PHASE1":2391,"PHASE1":2393,"PHASE2":2395,"PHASE3":2397,"PHASE4":2399,"NA":2401},{"trials":2392,"activeCount":72},[],{"trials":2394,"activeCount":72},[],{"trials":2396,"activeCount":72},[],{"trials":2398,"activeCount":72},[],{"trials":2400,"activeCount":72},[],{"trials":2402,"activeCount":72},[2403],{"nctId":2404,"briefTitle":2405,"status":232,"phases":2406,"primaryCompletion":1352,"completion":1352,"start":1523,"enrollment":2407,"conditions":2408,"interventions":2410},"NCT01048411","Trial to Investigate the Influence of the Homeopathic Remedy Naja-comp on Stroke Therapy in Geriatric Rehabilitation",[65],344,[2409],"Stroke",[2389],{"intervention":2412,"totalTrials":68,"cells":2413},"Tocilizumab",{"EARLY_PHASE1":2414,"PHASE1":2416,"PHASE2":2418,"PHASE3":2420,"PHASE4":2422,"NA":2424},{"trials":2415,"activeCount":72},[],{"trials":2417,"activeCount":72},[],{"trials":2419,"activeCount":72},[],{"trials":2421,"activeCount":72},[],{"trials":2423,"activeCount":72},[],{"trials":2425,"activeCount":72},[2426],{"nctId":2427,"briefTitle":2428,"status":232,"phases":2429,"primaryCompletion":2430,"completion":2431,"start":1238,"enrollment":2432,"conditions":2433,"interventions":2434},"NCT02778789","Comparing the Efficacy of Periarticular Bone Structure in Patients Treated With Either Tocilizumab or Tumor Necrosis Factor Blockers",[],"2017-09-30","2018-03-31",66,[659],[2412,2435],"TNF-alpha Inhibitor",{"intervention":2435,"totalTrials":68,"cells":2437},{"EARLY_PHASE1":2438,"PHASE1":2440,"PHASE2":2442,"PHASE3":2444,"PHASE4":2446,"NA":2448},{"trials":2439,"activeCount":72},[],{"trials":2441,"activeCount":72},[],{"trials":2443,"activeCount":72},[],{"trials":2445,"activeCount":72},[],{"trials":2447,"activeCount":72},[],{"trials":2449,"activeCount":72},[2450],{"nctId":2427,"briefTitle":2428,"status":232,"phases":2451,"primaryCompletion":2430,"completion":2431,"start":1238,"enrollment":2432,"conditions":2452,"interventions":2453},[],[659],[2412,2435],{"intervention":2455,"totalTrials":68,"cells":2456},"Nivolumab",{"EARLY_PHASE1":2457,"PHASE1":2459,"PHASE2":2461,"PHASE3":2463,"PHASE4":2465,"NA":2467},{"trials":2458,"activeCount":72},[],{"trials":2460,"activeCount":72},[],{"trials":2462,"activeCount":72},[],{"trials":2464,"activeCount":72},[],{"trials":2466,"activeCount":72},[],{"trials":2468,"activeCount":72},[2469],{"nctId":2470,"briefTitle":2471,"status":232,"phases":2472,"primaryCompletion":2473,"completion":2474,"start":2475,"enrollment":2476,"conditions":2477,"interventions":2479},"NCT03453892","Investigation of the Timely-coordinated Therapy of Patients With Metastatic Cancer by Radiotherapy Together With Immune Checkpoint Inhibition",[],"2021-02-28","2022-12-30","2017-04-01",150,[2478],"Metastatic Cancer",[2455,2480,2481],"Pembrolizumab","Ipilimumab",{"intervention":2480,"totalTrials":68,"cells":2483},{"EARLY_PHASE1":2484,"PHASE1":2486,"PHASE2":2488,"PHASE3":2490,"PHASE4":2492,"NA":2494},{"trials":2485,"activeCount":72},[],{"trials":2487,"activeCount":72},[],{"trials":2489,"activeCount":72},[],{"trials":2491,"activeCount":72},[],{"trials":2493,"activeCount":72},[],{"trials":2495,"activeCount":72},[2496],{"nctId":2470,"briefTitle":2471,"status":232,"phases":2497,"primaryCompletion":2473,"completion":2474,"start":2475,"enrollment":2476,"conditions":2498,"interventions":2499},[],[2478],[2455,2480,2481],{"intervention":2481,"totalTrials":68,"cells":2501},{"EARLY_PHASE1":2502,"PHASE1":2504,"PHASE2":2506,"PHASE3":2508,"PHASE4":2510,"NA":2512},{"trials":2503,"activeCount":72},[],{"trials":2505,"activeCount":72},[],{"trials":2507,"activeCount":72},[],{"trials":2509,"activeCount":72},[],{"trials":2511,"activeCount":72},[],{"trials":2513,"activeCount":72},[2514],{"nctId":2470,"briefTitle":2471,"status":232,"phases":2515,"primaryCompletion":2473,"completion":2474,"start":2475,"enrollment":2476,"conditions":2516,"interventions":2517},[],[2478],[2455,2480,2481]]